Endo Gains Phase II Oral Mucositis Agent With RxKinetix Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Agreement is in line with Endo’s strategy of expanding into therapeutic areas complementary to pain.
You may also be interested in...
Opana Uptake Slower Than Anticipated, But Script Growth Is On The Rise
Scripts for Endo's oral oxymorphone reached 1,137 the week of Sept. 29, according to IMS weekly trend data.
Endo To Launch Opana ER Oxymorphone With Two Risk Management Programs
The firm will add 220 sales reps to support the July launch of the extended-release and immediate-release opioid analgesics.
Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.